Should I buy or sell Prelude Therapeutics stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Prelude Therapeutics in the last year. There are currently 1 sell rating and 2 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "reduce" PRLD shares. View PRLD analyst ratings or view top-rated stocks .

What is Prelude Therapeutics' stock price target for 2024?

3 equities research analysts have issued 12 month price targets for Prelude Therapeutics' shares. Their PRLD share price targets range from $4.00 to $7.00. On average, they expect the company's share price to reach $5.25 in the next twelve months. This suggests a possible upside of 41.1% from the stock's current price. View analysts price targets for PRLD or view top-rated stocks among Wall Street analysts .

How have PRLD shares performed in 2024?

Prelude Therapeutics' stock was trading at $4.27 at the beginning of 2024. Since then, PRLD stock has decreased by 12.9% and is now trading at $3.72. View the best growth stocks for 2024 here .

When is Prelude Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024. View our PRLD earnings forecast .

How were Prelude Therapeutics' earnings last quarter?

Prelude Therapeutics Incorporated (NASDAQ:PRLD) released its quarterly earnings results on Thursday, February, 15th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.50) by $0.03.

What ETFs hold Prelude Therapeutics' stock?

ETFs with the largest weight of Prelude Therapeutics (NASDAQ:PRLD) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR) . Loncar China Biopharma ETF (CHNA) .

When did Prelude Therapeutics IPO?

Prelude Therapeutics (PRLD) raised $149 million in an initial public offering (IPO) on Friday, September 25th 2020. The company issued 8,300,000 shares at $17.00-$19.00 per share. Morgan Stanley, Goldman Sachs and BofA Securities served as the underwriters for the IPO.

How do I buy shares of Prelude Therapeutics?

Shares of PRLD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:PRLD

Prelude Therapeutics (PRLD) Stock Price, News & Analysis

→ The Hard Truth About Investing For Retirement (From Insiders Exposed) (Ad)

Free PRLD Stock Alerts

$3.72

+0.28 (+8.14%)

(As of 04/19/2024 ET)

Compare

Today's Range: $3.45
▼
$3.86
50-Day Range: $3.12
▼
$5.63
52-Week Range: $1.66
▼
$6.89

Volume: 57,910 shs
Average Volume: 39,476 shs
Market Capitalization: $204.30 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $5.25

Get Prelude Therapeutics alerts:

Prelude Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Reduce
1.67 Rating Score
Upside/Downside: 41.1% Upside
$5.25 Price Target
Short Interest: Healthy
1.84% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.88) to ($1.74) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.50 out of 5 stars

Medical Sector

434th out of 911 stocks

Pharmaceutical Preparations Industry

199th out of 419 stocks

2.8

Analyst's Opinion

Consensus Rating
Prelude Therapeutics has received a consensus rating of Reduce. The company's average rating score is 1.67, and is based on no buy ratings, 2 hold ratings, and 1 sell rating.
Amount of Analyst Coverage
Prelude Therapeutics has only been the subject of 2 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
1.84% of the float of Prelude Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Prelude Therapeutics has a short interest ratio ("days to cover") of 9.1.
Change versus previous month
Short interest in Prelude Therapeutics has recently decreased by 3.31%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Prelude Therapeutics does not currently pay a dividend.
Dividend Growth
Prelude Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for PRLD.

2.1

News and Social Media Coverage

News Sentiment
Prelude Therapeutics has a news sentiment score of 0.72. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.51 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Prelude Therapeutics this week, compared to 1 article on an average week.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Prelude Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
79.54% of the stock of Prelude Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
79.72% of the stock of Prelude Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Prelude Therapeutics are expected to grow in the coming year, from ($1.88) to ($1.74) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Prelude Therapeutics is -1.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Prelude Therapeutics is -1.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Prelude Therapeutics has a P/B Ratio of 0.86. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad DTI

This company has increased its dividend every year for 54 years

There are three basic steps to building the Ultimate Dividend Portfolio. Step #1 is to Get The High Yields! So an index fund like the SPY, paying only 1.5% a year, isn’t going to cut it. But a company like Altria Group (MO) will.

Click here to get them (for Free).

About Prelude Therapeutics Stock (NASDAQ:PRLD)

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.

PRLD Stock Price History

30 days | 90 days | 365 days | Advanced Chart

PRLD Stock News Headlines

April 13, 2024 | finance.yahoo.com

Several Insiders Invested In Prelude Therapeutics Flagging Positive News

April 13, 2024 | americanbankingnews.com

Prelude Therapeutics (NASDAQ:PRLD) Trading Up 7.7%

April 20, 2024 | Tranzact (Ad)

What is Medicare Supplement Insurance?

Original Medicare helps covers a lot of hospital and medical services, but it still leaves some out- of- pocket medical costs to recipients. Make sure your family’s nest egg is protected from unpredictable medical expenses. Consider applying for a Medicare Supplement Insurance Plan that travels with you.

April 9, 2024 | globenewswire.com

Prelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual Meeting

March 30, 2024 | morningstar.com

Prelude Therapeutics Inc Ordinary Shares PRLD

March 16, 2024 | finance.yahoo.com

PRLD Apr 2024 5.000 call

March 13, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Clearside Biomedical (CLSD) and Prelude Therapeutics (PRLD)

March 5, 2024 | globenewswire.com

Prelude Announces Acceptance of Multiple Preclinical Abstracts at the 2024 AACR Annual Meeting

April 20, 2024 | Tranzact (Ad)

What is Medicare Supplement Insurance?

February 29, 2024 | globenewswire.com

Prelude Therapeutics to Participate in Barclays Global Healthcare Conference

February 17, 2024 | finance.yahoo.com

Here's Why We're Watching Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Situation

February 17, 2024 | msn.com

New Accounting & Financial Operations Risk for Prelude Therapeutics, Inc. – What’s the Latest?

February 16, 2024 | msn.com

Prelude Therapeutics files to sell 7.94M shares for holders

February 16, 2024 | markets.businessinsider.com

Prelude Therapeutics Incorporated Registered Shs

February 15, 2024 | finance.yahoo.com

Prelude Therapeutics Reports Full Year 2023 Financial Results and Outlines Key Objectives for 2024

February 15, 2024 | globenewswire.com

Prelude Therapeutics Reports Full Year 2023 Financial Results and Outlines Key Objectives for 2024

February 5, 2024 | seekingalpha.com

Prelude Therapeutics: Interesting Pipeline That Is Too Early To Warrant My Buy

January 14, 2024 | finance.yahoo.com

Prelude Therapeutics Incorporated (NASDAQ:PRLD) is definitely on the radar of hedge funds investors who own 33% of the company

December 19, 2023 | msn.com

Morgan Stanley Downgrades Prelude Therapeutics (PRLD)

December 19, 2023 | markets.businessinsider.com

Morgan Stanley Downgrades Prelude Therapeutics: Here's What You Need To Know

December 18, 2023 | nasdaq.com

Prelude Therapeutics Incorporated Common Stock (PRLD)

December 11, 2023 | finance.yahoo.com

Prelude Therapeutics Announces $25 Million Private Placement

November 20, 2023 | benzinga.com

Prelude Therapeutics Stock (NASDAQ:PRLD) Dividends: History, Yield and Dates

November 5, 2023 | finance.yahoo.com

Prelude Therapeutics Insiders Are Down US$149k But Regain Some Losses

November 3, 2023 | finance.yahoo.com

Q3 2023 Abcellera Biologics Inc Earnings Call

November 1, 2023 | finance.yahoo.com

Prelude Announces Strategic Pipeline Progress and Updates, including its Partnership with AbCellera, and Reports Third Quarter Financial Results

November 1, 2023 | financialpost.com

Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in Oncology

See More Headlines

Receive PRLD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Prelude Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/15/2024
Today: 4/20/2024
Next Earnings (Estimated): 5/13/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:PRLD
CUSIP: N/A
CIK: 1678660
Web: www.preludetx.com
Phone: 302-467-1280
Fax: N/A
Employees: 128
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $5.25
High Stock Price Target: $7.00
Low Stock Price Target: $4.00
Potential Upside/Downside: +41.1%
Consensus Rating: Reduce
Rating Score (0-4): 1.67
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.04)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-121,830,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -53.39%
Return on Assets: -48.01%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 10.79
Quick Ratio: 10.79

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $4.32 per share
Price / Book: 0.86

Miscellaneous

Outstanding Shares: 54,920,000
Free Float: 11,237,000
Market Cap: $204.30 million
Optionable: Optionable
Beta: 1.51

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Dr. Krishna Vaddi D.V.M. (Age 58)
Ph.D., Founder, CEO & Director
Comp: $805.91k
Dr. Edna Huang M.D. (Age 51)
President & Chief Medical Officer
Comp: $563.55k
Dr. Peggy A. Scherle Ph.D. (Age 63)
Chief Scientific Officer
Comp: $868.62k
Mr. Laurent Chardonnet M.B.A. (Age 59)
Chief Financial Officer
Ms. Aimee Crombie Ph.D.
Senior VP and Head of Strategic Planning & Operations
Dr. Madhu Pudipeddi Ph.D.
Senior Vice President of Technical Operations
Lindsey Trickett
Vice President of Investor Relations
Mr. Bryant David Lim J.D. (Age 53)
Chief Legal Officer & Corporate Secretary
Ms. Michele Porreca M.B.A.
Chief People Officer
Dr. Andrew P. Combs Ph.D. (Age 58)
Executive VP & Head of Chemistry
Comp: $562.46k

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

PRLD Stock Analysis - Frequently Asked Questions

Should I buy or sell Prelude Therapeutics stock right now?: 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Prelude Therapeutics in the last year. There are currently 1 sell rating and 2 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "reduce" PRLD shares.
View PRLD analyst ratings or view top-rated stocks.
What is Prelude Therapeutics' stock price target for 2024?: 3 equities research analysts have issued 12 month price targets for Prelude Therapeutics' shares. Their PRLD share price targets range from $4.00 to $7.00. On average, they expect the company's share price to reach $5.25 in the next twelve months. This suggests a possible upside of 41.1% from the stock's current price.
View analysts price targets for PRLD or view top-rated stocks among Wall Street analysts.
How have PRLD shares performed in 2024?: Prelude Therapeutics' stock was trading at $4.27 at the beginning of 2024. Since then, PRLD stock has decreased by 12.9% and is now trading at $3.72.
View the best growth stocks for 2024 here.
When is Prelude Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024.
View our PRLD earnings forecast.

How were Prelude Therapeutics' earnings last quarter?: Prelude Therapeutics Incorporated (NASDAQ:PRLD) released its quarterly earnings results on Thursday, February, 15th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.50) by $0.03.
What ETFs hold Prelude Therapeutics' stock?: ETFs with the largest weight of Prelude Therapeutics (NASDAQ:PRLD) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR).Loncar China Biopharma ETF (CHNA).
When did Prelude Therapeutics IPO?: Prelude Therapeutics (PRLD) raised $149 million in an initial public offering (IPO) on Friday, September 25th 2020. The company issued 8,300,000 shares at $17.00-$19.00 per share. Morgan Stanley, Goldman Sachs and BofA Securities served as the underwriters for the IPO.
How do I buy shares of Prelude Therapeutics?: Shares of PRLD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PRLD) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial